Načítá se...
Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience
BACKGROUND: Few data are available on compliance and safety of adjuvant chemotherapy when indicated in elderly breast cancer patients; CMF (cyclophosphamide, methotrexate, fluorouracil) can be reasonably considered the most widely accepted standard of treatment. METHODS: We retrospectively reviewed...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2005
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1079800/ https://ncbi.nlm.nih.gov/pubmed/15790416 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-5-30 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|